{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:02:42Z","timestamp":1784350962632,"version":"3.55.0"},"reference-count":33,"publisher":"Keio Journal of Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Keio J. Med.","Keio j. med"],"published-print":{"date-parts":[[2026]]},"DOI":"10.2302\/kjm.2025-0019-oa","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:10:59Z","timestamp":1783980659000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Non-sedating and Sedating Histamine H&lt;sub&gt;1&lt;\/sub&gt;-receptor          Antagonist Premedication for Preventing Subcutaneous Daratumumab-associated          Infusion-related Reactions: A Multicenter Retrospective Observational Study"],"prefix":"10.2302","author":[{"given":"Mayu","family":"Yakumaru-suzukawa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacy, Keio University Graduate School of              Pharmaceutical Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Aomori","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Keio University Faculty of Pharmacy, Tokyo,              Japan"},{"name":"Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization Sendai Medical              Center, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hayama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, Ota,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Tanigawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokai University Medical Hospital, Isehara,              Japan"},{"name":"Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer              Institute Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kanagawa Prefectural Keiyukai Keiyu Hospital,              Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Uchiike","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Amagasa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Japanese Red Cross Ashikaga Hospital, Ashikaga,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokai University Medical Hospital, Isehara,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kiyomiya","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Keio University Faculty of Pharmacy, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Keio University Graduate School of              Pharmaceutical Sciences, Tokyo, Japan"},{"name":"Division of Clinical Pharmacy, Keio University Faculty of Pharmacy, Tokyo,              Japan"},{"name":"Department of Pharmacy, Keio University Hospital, Tokyo,              Japan"},{"name":"Department of Clinical Pharmacy, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakazu","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacy, Keio University Graduate School of              Pharmaceutical Sciences, Tokyo, Japan"},{"name":"Division of Clinical Pharmacy, Keio University Faculty of Pharmacy, Tokyo,              Japan"},{"name":"Department of Pharmacy, Keio University Hospital, Tokyo,              Japan"},{"name":"Department of Clinical Pharmacy, Keio University School of Medicine, Tokyo,              Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1082","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vogel WH: Infusion reactions: diagnosis,          assessment, and management. Clin J Oncol Nurs 2010; 14: E10\u2013E21. PMID:20350882          https:\/\/doi.org\/10.1188\/10.CJON.E10-E21","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"2","unstructured":"2.Cancer Therapy Evaluation Program: Common          Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sanchez L, Wang Y, Siegel DS, Wang ML:          Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple          myeloma. J Hematol Oncol 2016; 9: 51. PMID:27363983          https:\/\/doi.org\/10.1186\/s13045-016-0283-0","DOI":"10.1186\/s13045-016-0283-0"},{"key":"4","unstructured":"4.Janssen Pharmaceutical K. K.: DARZALEX package          insert. 2023."},{"key":"5","unstructured":"5.Jannsen Pharmaceutical Companies: DARZALEX          Label. 2024."},{"key":"6","unstructured":"6.Janssen-Cilag International NV: DARZALEX:          Product Information. 2024."},{"key":"7","unstructured":"7.Janssen Pharmaceutical K. K.: drug information          booklet of DARZQURO \u201cinterview form\u201d. 2023; (Japanese)."},{"key":"8","unstructured":"8.Jannsen Pharmaceutical Companies: DARZALEX          FASPRO Label. 2024."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Zhang D, Tashiro M, Shibuya K, Okamura N, Funaki          Y, Yoshikawa T, Kato M, Yanai K: Next-day residual sedative effect after nighttime          administration of an over-the-counter antihistamine sleep aid, diphenhydramine, measured          by positron emission tomography. J Clin Psychopharmacol 2010; 30: 694\u2013701. PMID:21105284          https:\/\/doi.org\/10.1097\/JCP.0b013e3181fa8526","DOI":"10.1097\/JCP.0b013e3181fa8526"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Okamura N, Yanai K, Higuchi M, Sakai J, Iwata R,          Ido T, Sasaki H, Watanabe T, Itoh M: Functional neuroimaging of cognition impaired by a          classical antihistamine, d \u2010chlorpheniramine. Br J Pharmacol 2000; 129: 115\u2013123.          PMID:10694210 https:\/\/doi.org\/10.1038\/sj.bjp.0702994","DOI":"10.1038\/sj.bjp.0702994"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Beaucage-Charron J, Gaudet L, Lamothe S,          Pelletier C, P\u00e9pin AS, Roy V, Charpentier F, Lordkipanidz\u00e9 M, Projean D, Bouchard P,          Picard M: A randomized double-blind feasibility study comparing cetirizine and          diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the          PREMED-F1 study. Support Care Cancer 2022; 30: 3389\u20133399. PMID:34997314          https:\/\/doi.org\/10.1007\/s00520-021-06734-4","DOI":"10.1007\/s00520-021-06734-4"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Durham CG, Thotakura D, Sager L, Foster J,          Herrington JD: Cetirizine versus diphenhydramine in the prevention of chemotherapy-related          hypersensitivity reactions. J Oncol Pharm Pract 2019; 25: 1396\u20131401. PMID:30419768          https:\/\/doi.org\/10.1177\/1078155218811505","DOI":"10.1177\/1078155218811505"},{"key":"13","unstructured":"13. Iwamoto D, Ide T, Mimura A, Tsuchiya H, Yamaori          S: Retrospective Study of Infusion Reactions during the First Administration of          Daratumumab Intravenous Infusion in Patients with Multiple Myeloma. J Jpn Soc Hosp Pharm          2022; 58: 61\u201366 (Japanese)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.Matsui N, Ishihara N, Mochizuki Y, Tamaki H,          Nishimura N andNaora K: Inhibitory Effect on Rituximab-induced Infusion Reaction by          Premedication with Fexofenadine or Bepotastine. Iryo Yakugaku (Jpn. J. Pharm. Health Care          Sci.) 2019; 45 , 396\u2013403 (Japanese).","DOI":"10.5649\/jjphcs.45.396"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Maeda K, Hisaka A, Ito K, Ohno Y, Ishiguro A,          Sato R, Nagai N: Classification of drugs for evaluating drug interaction in drug          development and clinical management. Drug Metab Pharmacokinet 2021; 41: 100414.          PMID:34666290 https:\/\/doi.org\/10.1016\/j.dmpk.2021.100414","DOI":"10.1016\/j.dmpk.2021.100414"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Holmes JP, Peguero JA, Garland RC, North J, Young          S, Brent LD, Joseph-Ridge N: Intravenous Cetirizine vs Intravenous Diphenhydramine for the          Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2          Study. J Infus Nurs 2021; 44: 315\u2013322. PMID:34555839          https:\/\/doi.org\/10.1097\/NAN.0000000000000444","DOI":"10.1097\/NAN.0000000000000444"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Devalia JL, Hanotte F, Baltes E, De Vos C: A          randomized, double\u2010blind, crossover comparison among cetirizine, levocetirizine, and ucb          28557 on histamine\u2010induced cutaneous responses in healthy adult volunteers. Allergy 2001;          56: 50\u201357. PMID:11167352 https:\/\/doi.org\/10.1034\/j.1398-9995.2001.00726.x","DOI":"10.1034\/j.1398-9995.2001.00726.x"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Shibayama H, Matsumoto M, Kosugi H, Shibayama K,          Yamazaki H, Iida S: Subcutaneous delivery of daratumumab in Japanese patients with          relapsed\/refractory multiple myeloma. Int J Hematol 2021; 113: 112\u2013121. PMID:32915384          https:\/\/doi.org\/10.1007\/s12185-020-02985-9","DOI":"10.1007\/s12185-020-02985-9"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Usmani SZ, Nahi H, Mateos MV, van de Donk NW,          Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T,          Clemens PL, Luo M, Liu K, San-Miguel J: Subcutaneous delivery of daratumumab in relapsed          or refractory multiple myeloma. Blood 2019; 134: 668\u2013677. PMID:31270103          https:\/\/doi.org\/10.1182\/blood.2019000667","DOI":"10.1182\/blood.2019000667"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Iida S, Ishikawa T, Min CK, Kim K, Yeh SP, Usmani          SZ, Mateos MV, Nahi H, Heuck C, Qin X, Parasrampuria DA, Gries KS, Qi M, Bahlis N, Ito S:          Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma:          subgroup analyses of the noninferiority, phase 3 COLUMBA study. Ann Hematol 2021; 100:          1065\u20131077. PMID:33599794 https:\/\/doi.org\/10.1007\/s00277-021-04405-2","DOI":"10.1007\/s00277-021-04405-2"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K,          Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour          L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C:          Subcutaneous daratumumab plus standard treatment regimens in patients with multiple          myeloma across lines of therapy (PLEIADES): an open\u2010label Phase II study. Br J Haematol          2021; 192: 869\u2013878. PMID:33216361 https:\/\/doi.org\/10.1111\/bjh.16980","DOI":"10.1111\/bjh.16980"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi          S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV,          Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H,          Vermeulen J, Carson R, Sonneveld P, Alegre Amor A, Baldini L, Beksac M, Belotti A,          Benboubker L, Besemer B, Besisik S, Bila J, Boccadoro M, Cavo M, De La Rubia Comos J,          Delimpasi S, Dimopoulos MA, Doyen C, Dytfeld D, Engelhardt M, Facon T, Fo\u00e0 R, Goldschmidt          H, Grosicki S, Hajek R, Hayri Ozsan G, Hulin C, Iversen B, Karlin L, Katodritou E, Knop S,          Kyrtsonis MC, Lahuerta JJ, Leleu X, Martinez Chamorro C, Mateos Manteca MV, Meuleman N,          Minnema M, Moreau P, Offidani M, Oriol Rocafiguera A, Pehlivan M, Pour L, Roerdink HT,          Rosinol Dacsh L, Salwender H, Sonneveld P, Symeonidis A, Toftmann Hansen C, Tuglular T,          Unal A, Vlummens P, Vural F, Wu KL, Zweegman S, APOLLO Trial Investigators: Daratumumab          plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in          previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.          Lancet Oncol 2021; 22: 801\u2013812. PMID:34087126          https:\/\/doi.org\/10.1016\/S1470-2045(21)00128-5","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H,          Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti          A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NW, Katodritou E, Schjesvold F, Sureda          Balari A, Rosi\u00f1ol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A,          Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EM,          Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Blad\u00e9 J,          Moreau P, Investigators PT, PERSEUS Trial Investigators: Daratumumab, bortezomib,          lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024; 390: 301\u2013313.          PMID:38084760 https:\/\/doi.org\/10.1056\/NEJMoa2312054","DOI":"10.1056\/NEJMoa2312054"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev          V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Blad\u00e9 J, Moreau P, Kaiser M,          Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson          T, Lantz K, O\u2019Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ:          Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory          multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase          3 trial. Lancet Haematol 2020; 7: e370\u2013e380. PMID:32213342          https:\/\/doi.org\/10.1016\/S2352-3026(20)30070-3","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Mateos MV, Rigaudeau S, Basu S, Spicka I, Schots          R, Wrobel T, Cook G, Beksac M, Gries KS, Kudva A, Tromp B, Van Rampelbergh R, Pei H,          Wroblewski S, Carson R, Delioukina M, White D: Switching to daratumumab SC from IV is safe          and preferred by patients with multiple myeloma. J Oncol Pharm Pract 2023; 29: 1172\u20131177.          PMID:36067063 https:\/\/doi.org\/10.1177\/10781552221103551","DOI":"10.1177\/10781552221103551"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Soefje SA, Carpenter C, Carlson K, Awasthi S, Lin          TS, Kaila S, Tarjan D, Kayal N, Kirkup C, Wagner TE, Gray KS, Kumar S: Clinical          Administration Characteristics of Subcutaneous and Intravenous Administration of          Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers. JCO Oncol          Pract 2023; 19: e542\u2013e549. PMID:36758192          https:\/\/doi.org\/10.1200\/OP.22.00421","DOI":"10.1200\/OP.22.00421"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Bachert C, Bousquet J, Canonica GW, Durham SR,          Klimek L, Mullol J, Van Cauwenberge PB, Van Hamm\u00e9e G, Group XS, XPERT Study Group:          Levocetirizine improves quality of life and reduces costs in long-term management of          persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838\u2013844. PMID:15480324          https:\/\/doi.org\/10.1016\/j.jaci.2004.05.070","DOI":"10.1016\/j.jaci.2004.05.070"},{"key":"28","unstructured":"28.Takata Pharmaceutical Co, Ltd: drug          information booklet of POLARAMINE \u201cinterview form\u201d. 2018; (Japanese)."},{"key":"29","unstructured":"29.Kowa Company, Ltd: drug information booklet of          RESTAMIN KOWA \u201cinterview form\u201d. 2022; (Japanese)."},{"key":"30","unstructured":"30. Tashiro M, Inami A, Takeda K, Miyake M, Hiraoka          K, Yanai K: Comparison of driving simulator performances in young and elderly adults          following oral administration of antihistamines. Recent Advances in Clinical Pharmacology          2015; 36: 177\u2013186."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nakano S, Sunami Y, Irie S, Matsuguma K,          Tsukikawa H: The Effect of Loratadine on Psychomotor Function in Healthy Japanese          Subjects: Comparison with d-Chlorpheniramine Maleate and Placebo in a Double-Blind 4-Way          Crossover Study. Rinsho yakuri\/Jpn. J Clin Pharm Ther 2007; 38: 401\u2013407.","DOI":"10.3999\/jscpt.38.401"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Yanai K, Yoshikawa T, Yanai A, Nakamura T, Iida          T, Leurs R, Tashiro M: The clinical pharmacology of non-sedating antihistamines. Pharmacol          Ther 2017; 178: 148\u2013156. PMID:28457804          https:\/\/doi.org\/10.1016\/j.pharmthera.2017.04.004","DOI":"10.1016\/j.pharmthera.2017.04.004"},{"key":"33","unstructured":"33.Bristol-Myers Squibb K. K.: drug information          booklet of LenaDex \u201cinterview form\u201d. 2024; (Japanese)."}],"container-title":["The Keio Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/advpub\/0\/advpub_2025-0019-OA\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:15:05Z","timestamp":1784348105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kjm\/advpub\/0\/advpub_2025-0019-OA\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":33,"URL":"https:\/\/doi.org\/10.2302\/kjm.2025-0019-oa","relation":{},"ISSN":["0022-9717","1880-1293"],"issn-type":[{"value":"0022-9717","type":"print"},{"value":"1880-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025-0019-OA"}}